Start here if you're new
what it is
Huntsman makes industrial chemicals used in insulation, coatings, composites, and other materials tied to construction, autos, and manufacturing.
how it gets paid
Last year Huntsman made $5.7B in revenue. U.S. and Canada was the main engine at $2.00B, or 35% of sales.
why growth slowed
Revenue fell 5.8% last year. An unplanned shutdown at the rotterdam polyurethanes plant and ongoing global mdi overcapacity mean that the top and bottom lines are likely to remain depressed.
what just happened
Revenue of $4.3B, but earnings still came in below expectations.
At a glance
B+ balance sheet — decent shape, but not bulletproof
25/100 earnings predictability — expect surprises
7.6% dividend yield — cash in your pocket every quarter
4.0% return on capital — nothing to write home about
xvary composite: 47/100 — below average
What they do
Huntsman makes industrial chemicals used in insulation, coatings, composites, and other materials tied to construction, autos, and manufacturing.
Huntsman wins by being embedded in ugly but necessary supply chains. It runs 60 plants across more than 25 countries and sells into over 100 nations, so your customers can keep buying from one supplier instead of juggling a dozen. Polyurethanes alone made up 65% of 2024 sales, which gives Huntsman scale in its biggest category.
How they make money
$5.7B
annual revenue · their business grew -5.8% last year
U.S. and Canada
$2.00B
Asia/Pacific
$1.71B
Europe
$1.48B
Rest of World
$0.51B
The products that matter
makes insulation chemicals
Polyurethanes
$3.7B · 65% of revenue
this is the core business at $3.7B, and its size means one weak end market can drag the whole company.
65% of rev
makes performance chemicals
Performance Products
$1.0B · 18% of revenue
it contributes $1.0B of sales, which helps diversify the mix, but it is still less than one-fifth of the business.
18% of rev
makes specialty materials
Advanced Materials
$1.0B · 17% of revenue
another $1.0B segment, but at 17% of revenue it is too small to offset sustained weakness in polyurethanes.
17% of rev
Key numbers
7.6%
dividend yield
You are being paid a high cash yield, but that payout sits next to expected losses in 2026.
$1.6B
long-term debt
That is 45% of capital, which means debt still matters a lot for a company with weak returns.
4.0%
return on capital
Return on capital → profit earned on money invested in the business → so what: 4.0% is weak for a cyclical manufacturer.
$5.7B
annual revenue
The business is still large, but revenue fell 5.8% vs. prior year, which tells you scale is not fixing demand.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 50 / 100
- long-term debt $1.6B (45% of capital)
- net profit margin 2.9% — keeps 3 cents of every dollar in revenue
- return on equity 6% — $0.06 profit for every $1 investors have put in
B+ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in HUN 3 years ago → it's now worth $4,260.
The index would have given you $14,770.
source: institutional data · total return
What just happened
missed estimates
Revenue of $4.3B, but earnings still came in below expectations.
EPS was -$0.51 versus a -$0.46 estimate, a 10.87% miss, according to Yahoo Finance. Gross margin was 13.6%, which is thin for a company trying to climb out of an earnings hole.
$4.3B
revenue
$0.51
eps
13.6%
gross margin
the number that mattered
Gross margin at 13.6% is the real tell, because thin margins leave very little buffer when sales are already falling.
-
things aren’t looking so good for huntsman.other than the june quarter of 2024, the chemical maker hasn’t made a profit since the second quarter of 2023.
-
moreover, sales have been progressively declining since 2021.
-
we don’t look for things to have improved in the fourth quarter.an unplanned shutdown at the rotterdam polyurethanes plant and ongoing global mdi overcapacity mean that the top and bottom lines are likely to remain depressed.
-
our outlook for 2026 is not too optimistic.we see no short-term catalyst to give us hope that huntsman’s operations will improve much, if at all. the company will probably continue to be no stranger to unplanned facility shutdowns as capital assets are becoming long in the tooth. meanwhile, demand for huntsman’s chemicals from the automotive, construction, and home building segments will probably be tepid. rising raw material costs and increasingly time-consuming and convoluted supply chains mean thinner margins.
-
high import tariffs aren’t helping, since 72% of the company’s volume emanates from abroad (including canada).
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is chronic unprofitability in a polyurethanes-heavy business.
high
chronic unprofitability
analysts expect -$0.30 in EPS for fy2026. that follows a stretch where profits have already been scarce.
if losses persist, the market stops treating the 7.6% yield as income and starts treating it as a warning label.
high
dividend sustainability
a 7.6% yield looks generous until you pair it with negative earnings. the payout is the bull case and the pressure point at the same time.
if management cuts the dividend, one of the stock's few remaining supports goes with it.
med
balance sheet drag
long-term debt stands at $1.6B, or 45% of capital. that is manageable in good years and less comfortable in bad ones.
thin margins plus leverage is how a cyclical downturn turns from annoying to expensive.
med
trade and plant disruption
72% of volume comes from abroad, and the rotterdam polyurethanes shutdown already showed how operational issues can hit results.
when the biggest segment is 65% of revenue, one disruption can travel through the entire income statement.
a $5.7B revenue base, 5.5% operating margin, and -$0.30 EPS outlook leave very little room to defend a 7.6% yield.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
next earnings report
april 30, 2026 is the next real test. if revenue stays near $1.5B and losses widen from -$0.14, the turnaround story gets thinner.
margin
gross margin direction
13.2% gross margin was the key number last quarter. you want to see that move up, not just management talking about eventual savings.
cycle
polyurethanes demand and pricing
polyurethanes is 65% of revenue. if MDI overcapacity persists, the largest segment keeps acting like an anchor.
risk
dividend coverage
the stock can survive weak quarters more easily than it can survive a broken income case plus a questioned dividend. that is the line to watch.
Analyst rankings
short-term outlook
below average
outlook rank 4 — in human-speak, analysts expect this stock to lag most others in the near term.
risk profile
average
risk rank 3 — not a bunker stock, not the most dangerous name on the screen either.
chart momentum
below average
momentum rank 4 — the tape is not confirming a rebound yet.
earnings predictability
25 / 100
low predictability means the quarterly numbers can swing hard. if you own it, expect surprises.
source: institutional data
Institutional activity
institutions have been net buying for 3 consecutive quarters — 206 buyers vs. 146 sellers in 3q2025. total institutional holdings: 0.2B shares. net buying for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$8
$22
$12
current price
$15
target midpoint · +30% from current · 3-5yr high: $18 (+55% · 15% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive